Insider trade

Director sold ~$515K of ROIV shares in the open market

Traded Jun 29, 2026 · Filed Jul 2, 2026

Why it stands out

A board member of Roivant Sciences sold $515K of Roivant Sciences shares. It happened by itself, for taxes or pay.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$514,869

Shares × reported transaction price

Timing vs results

40 days after results of May 20, 2026, 38 days before results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Filing box checked: sold under a Rule 10b5-1 plan

Only flagged when a footnote says so; never inferred

After	Stock	S&P 500	Difference
7 days	+4.8%	+0.9%	+3.9%
30 days	−5.2%	+1.7%	−6.9%
90 days	+4.1%	+2.4%	+1.7%

Past results only. Not a forecast.

The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.

2mo ago

Derivative exercise or conversion — not an open-market buy.

Automatic sale2mo ago

2mo ago

Derivative exercise or conversion — not an open-market buy.